Published in Neurourol Urodyn on January 01, 2008
Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol (2011) 1.01
Management of overactive bladder. Nat Rev Urol (2010) 0.85
Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. World J Urol (2011) 0.84
Measuring urgency in clinical practice. World J Urol (2009) 0.83
Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol (2009) 0.81
Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol (2012) 0.80
Changes of neuregulin-1 (NRG-1) expression in a rat model of overactive bladder induced by partial urethral obstruction: is NRG-1 a new biomarker of overactive bladder? BMC Urol (2013) 0.78
Association of urinary urgency and delay time of micturition in women with overactive bladder. Int Neurourol J (2014) 0.77
The overactive bladder. Ther Adv Urol (2010) 0.76
Urinary nerve growth factor in patients with detrusor overactivity. Ir J Med Sci (2014) 0.75
A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency. PLoS One (2014) 0.75
Epidural steroid injections in the management of a patient with spinal stenosis and urinary urgency. Nat Clin Pract Urol (2009) 0.75
Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder. Int Urogynecol J (2014) 0.75
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
American Urological Association guideline on the management of priapism. J Urol (2003) 3.77
AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol (2012) 1.81
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn (2012) 1.56
Chapter 1: The management of erectile dysfunction: an AUA update. J Urol (2005) 1.55
Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn (2010) 1.55
The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy. BJU Int (2013) 1.52
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Histologic comparison of pubovaginal sling graft materials: a comparative study. Urology (2008) 1.48
Overactive bladder: evaluation and management in primary care. Cleve Clin J Med (2005) 1.45
A randomized, controlled clinical trial of a novel intravesical pressure attenuation device for the treatment of stress urinary incontinence. J Urol (2013) 1.38
Early results of pubovaginal sling lysis by midline sling incision. Urology (2002) 1.37
AUA guideline on the pharmacologic management of premature ejaculation. J Urol (2004) 1.28
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Porcine dermis interposition graft for repair of high grade anterior compartment defects with or without concomitant pelvic organ prolapse procedures. J Urol (2004) 1.21
Approach to management of iatrogenic foreign bodies of the lower urinary tract following reconstructive pelvic surgery. J Urol (2012) 1.19
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol (2009) 1.11
Epidemiology of stress urinary incontinence in women. Curr Urol Rep (2011) 1.02
Patterns and predictors of urodynamics use in the United States. J Urol (2012) 1.02
Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology (2006) 1.01
Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Am J Pathol (2007) 0.98
Obturator foramen dissection for excision of symptomatic transobturator mesh. J Urol (2012) 0.98
Urethral injections for female stress incontinence. BJU Int (2006) 0.97
Histopathological evaluation of the uterosacral ligament: is this a dependable structure for pelvic reconstruction? BJU Int (2006) 0.97
The evaluation and treatment of nocturia: a consensus statement. BJU Int (2011) 0.97
Removal of transobturator midurethral sling for refractory thigh pain. Urology (2008) 0.96
Genitourinary fistula experience in Sierra Leone: review of 505 cases. J Urol (2009) 0.95
Sling failures: what's next? Curr Urol Rep (2004) 0.92
Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol (2010) 0.92
The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction. J Urol (2008) 0.91
Diagnosis and management of outlet obstruction in the female. Curr Opin Urol (2008) 0.91
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol (2009) 0.91
Encapsulation of a porcine dermis pubovaginal sling. J Urol (2003) 0.90
Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? Neurourol Urodyn (2005) 0.89
Pubovaginal sling and pelvic prolapse repair in women with occult stress urinary incontinence: effect on postoperative emptying and voiding symptoms. Urology (2002) 0.87
Biocompatibility assessment of synthetic sling materials for female stress urinary incontinence. J Urol (2007) 0.87
Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn (2012) 0.87
Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr Urol Rep (2010) 0.87
Nicotinic signaling ameliorates acute bladder inflammation induced by protamine sulfate or cyclophosphamide. J Urol (2008) 0.86
Vaginal mesh update. Curr Opin Urol (2012) 0.86
Vesicovaginal fistula following a transobturator midurethral sling procedure. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.86
The use of a multidisciplinary morbidity and mortality conference to incorporate ACGME general competencies. J Surg Educ (2011) 0.86
Pelvic organ prolapse (POP) surgery: the evidence for the repairs. BJU Int (2011) 0.84
Repeat urethrolysis after failed urethrolysis for iatrogenic obstruction. J Urol (2003) 0.84
Analysis of patient and technical factors associated with midurethral sling mesh exposure and perforation. Int J Urol (2014) 0.83
Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol (2005) 0.83
Management of obstructive voiding dysfunction after incontinence surgery: lessons learned. Urology (2003) 0.83
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol (2006) 0.83
Urethral bulking: a urology perspective. Urol Clin North Am (2012) 0.82
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clin Pharmacokinet (2004) 0.82
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol (2005) 0.82
Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. Neurourol Urodyn (2007) 0.82
Management of overactive bladder with transdermal oxybutynin. Rev Urol (2006) 0.81
Beyond collagen: injectable therapies for the treatment of female stress urinary incontinence in the new millennium. Urol Clin North Am (2002) 0.81
Mixed incontinence and cystocele: postoperative urge symptoms are not predicted by preoperative urodynamics. Int Urogynecol J (2010) 0.81
Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. Expert Opin Drug Metab Toxicol (2013) 0.80
Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Clin Ther (2013) 0.80
Safety and efficacy of sling for persistent stress urinary incontinence after bulking injection. Urology (2011) 0.80
Voiding dysfunction following removal of eroded synthetic mid urethral slings. J Urol (2006) 0.79
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol (2007) 0.79
Muscarinic receptors: what we know. Curr Urol Rep (2003) 0.79
UroLume stents: lessons learned. J Urol (2002) 0.79
Treatment of mixed urinary incontinence in women. Curr Opin Obstet Gynecol (2011) 0.79
Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol (2010) 0.78
Urodynamic patterns following ischemic spinal cord events. J Urol (2003) 0.78
Pubic osteomyelitis following bladder neck surgery using bone anchors: a report of 9 cases. J Urol (2002) 0.78
Tegresstrade mark Urethral Implant Phase III Clinical Experience and Product Uniqueness. Rev Urol (2005) 0.78
Interobserver variability when employing the IUGA/ICS classification system for complications related to prostheses and grafts in female pelvic floor surgery. Int Urogynecol J (2013) 0.78
Office urodynamics. Urol Clin North Am (2005) 0.78
Factors associated with exposure of transvaginally placed polypropylene mesh for pelvic organ prolapse. Int Urogynecol J (2012) 0.78
Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.77
Case reports: periurethral bulking agents and presumed urethral diverticula. Int Urogynecol J (2011) 0.77
Transdermal oxybutynin for overactive bladder. Urol Clin North Am (2006) 0.77
Using Coworker Observations to Promote Accountability for Disrespectful and Unsafe Behaviors by Physicians and Advanced Practice Professionals. Jt Comm J Qual Patient Saf (2016) 0.77
Medical malpractice claims risk in urology: an empirical analysis of patient complaint data. J Urol (2010) 0.76
Oxybutynin gel for the treatment of overactive bladder. Expert Opin Pharmacother (2012) 0.76
Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. BJU Int (2011) 0.76
Female urethral diverticula. Urol Clin North Am (2011) 0.76
Voiding dysfunction after removal of eroded slings. J Urol (2006) 0.75
Underactive bladder in women: is there any evidence? Curr Opin Urol (2016) 0.75
Duloxetine: a summary of published clinical experience. Rev Urol (2004) 0.75
Treatment of the overactive bladder: where we stand in 2003. Rev Urol (2003) 0.75
Fesoterodine fumarate. Drugs Today (Barc) (2010) 0.75
Postoperative pain outcomes after transvaginal mesh revision. Int Urogynecol J (2014) 0.75
Editorial comment. Do women with pure stress urinary incontinence need urodynamics? Urology (2009) 0.75
Editorial comment from Dr Dmochowski to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol (2011) 0.75
Antibiotic prophylaxis in urologic prosthetic surgery. Curr Pharm Des (2003) 0.75
Posterior-compartment repair: a urology perspective. Urol Clin North Am (2012) 0.75
Bladder neck pubovaginal slings. Expert Rev Med Devices (2005) 0.75
Incisional bladder hernia after rectus fascial sling. J Urol (2003) 0.75
The effects of isolated posterior compartment defects on lower urinary tract symptoms and urodynamic findings. BJU Int (2006) 0.75
Future studies of overactive bladder: the need for standardization. Urology (2002) 0.75